Meitheal Pharmaceuticals Launches Heparin Sodium Injection, USP in the United States
17 September 2019 - - US-based generic injectables company Meitheal Pharmaceuticals has launched its eight presentations of heparin sodium injection, USP in the United States, the company said.

Meitheal's partner, Nanjing King-Friend Biochemical Pharmaceutical company is an FDA-approved manufacturer of both active pharmaceutical ingredients and finished dosage form, supplying 15-20% of the finished dosage heparin market in the US.

The company is NKF's exclusive commercialisation arm for the US market, ensuring consistent and dedicated supply of heparin.

Meitheal primarily specializes in the development, manufacture, procurement, and sale of generic injectable pharmaceuticals, with 12 FDA-approved products covering indications for anti-infective, oncolytic and intensive care.

Furthermore, Meitheal has an expanding product portfolio and robust pipeline, including single and multi-dose vials, ready-to-use prefilled syringes and premixed bags.

As of the end of June 2019, Meitheal, directly or in combination with its partner(s), had 49 products in the research and development phase, 24 products under review by the FDA, and eight products to be launched in 2019.

Heparin is an intravenous or subcutaneous anticoagulant derived from porcine intestinal mucosa used to decrease the clotting ability of blood and help prevent harmful clots from forming in blood vessels.

Since 2017, Meitheal Pharmaceuticals has bridged critical gaps in the US healthcare market by supplying high quality, affordable generic injectables.

Its product range, from antibiotics, anticoagulants, and muscle relaxants to drugs used in chemotherapy, represents practical solutions for countless patients around the country, as well as Meitheal's commitment to their care.

The company is based in Chicago, Illinois.